| 1 |
Gao SH, Liu SZ, Wang GZ, et al. CXCL13 in cancer and other diseases: biological functions, clinical significance, and therapeutic opportunities [J]. Life (Basel, Switzerland), 2021, 11(12): 1282.
|
| 2 |
Masouris I, Klein M, Ködel U. The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection [J]. Expert Rev Anti Infect Ther, 2020, 18(9): 875-885.
|
| 3 |
Hughes CE, Nibbs RJB. A guide to chemokines and their receptors [J]. FEBS J, 2018, 285(16): 2944-2971.
|
| 4 |
Hussain M, Adah D, Tariq M, et al. CXCL13/CXCR5 signaling axis in cancer [J]. Life Sci, 2019, 227: 175-186.
|
| 5 |
Bian D, Chen Y. Bioinformatics analysis of prognostic significance and immune characteristics of CXC chemokine family in patients with lung adenocarcinoma [J]. Comput Math Methods Med, 2022, 2022: 3918926.
|
| 6 |
Pan Z, Zhu T, Liu Y, et al. Role of the CXCL13/CXCR5 axis in autoimmune diseases [J]. Frontiers In Immunology, 2022, 13: 850998.
|
| 7 |
Leth TA, Dessau RB, Møller JK. Discriminating between Lyme neuroborreliosis and other central nervous system infections by use of biomarkers CXCL13 and IL-6 [J]. Ticks Tick Borne Dis, 2022, 13(5): 101984.
|
| 8 |
Disano KD, Gilli F, Pachner AR. Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on "Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function" [J]. Fluids Barriers CNS, 2021, 18(1): 9.
|
| 9 |
Pilz G, Sakic I, Wipfler P, et al. Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction [J]. Fluids and Barriers of the CNS, 2020, 17(1): 7.
|
| 10 |
Pilz G, Wipfler P, Otto F, et al. Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study [J]. J Neuroinflammation, 2019, 16(1): 13.
|
| 11 |
Harrer C, Otto F, Pilz G, et al. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF [J]. Fluids Barriers CNS, 2021, 18(1): 40.
|
| 12 |
Rauer S, Kastenbauer S, Fingerle V, et al. Lyme neuroborreliosis [J]. Dtsch Arztebl Int, 2018, 115(45): 751-756.
|
| 13 |
Eckman EA, Clausen DM, Herdt AR, et al. Specificity and diagnostic utility of cerebrospinal fluid CXCL13 in Lyme neuroborreliosis [J]. Clin Infect Dis, 2021, 72(10): 1719-1726.
|
| 14 |
Rupprecht TA, Manz KM, Fingerle V, et al. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis [J]. Clin Microbiol Infect, 2018, 24(12): 1234-1240.
|
| 15 |
Strle F, Henningsson AJ, Strle K. Diagnostic utility of CXCL13 in Lyme neuroborreliosis [J]. Clin Infect Dis, 2021, 72(10): 1727-1729.
|
| 16 |
Henningsson AJ, Lager M, Brännström R, et al. The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis [J]. Eur J Clin Microbiol Infect Dis, 2018, 37(10): 1983-1991.
|
| 17 |
Knudtzen FC, Nilsson AC, Hovius JW, et al. The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study [J]. Eur J Clin Microbiol Infect Dis, 2020, 39(8): 1461-1470.
|
| 18 |
Wagner JN, Weis S, Kubasta C, et al. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients [J]. J Neurol, 2018, 265(1): 74-81.
|
| 19 |
Markowicz M, Schötta AM, Kundi M, et al. CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISA [J]. Ticks Tick Borne Dis, 2018, 9(5): 1137-1142.
|
| 20 |
Van Gorkom T, Van Arkel GHJ, Heron M, et al. The usefulness of two CXCL13 assays on cerebrospinal fluid for the diagnosis of lyme neuroborreliosis: a retrospective study in a routine clinical setting [J]. J Clin Microbiol, 2021, 59(9): e0025521.
|
| 21 |
Toczylowski K, Grygorczuk S, Osada J, et al. Evaluation of cerebrospinal fluid CXCL13 concentrations and lymphocyte subsets in tick-borne encephalitis [J]. Int J Infect Dis, 2020, 93: 40-47.
|
| 22 |
Albinsson B, Jääskeläinen AE, Värv K, et al. Multi-laboratory evaluation of ReaScan TBE IgM rapid test, 2016 to 2017 [J]. Euro Surveill, 2020, 25(12): 1900427.
|
| 23 |
Riccardi N, Antonello RM, Luzzati R, et al. Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment [J]. Eur J Intern Med, 2019, 62: 1-6.
|
| 24 |
Bogovič P, Lusa L, Korva M, et al. Inflammatory immune responses in the pathogenesis of Tick-borne encephalitis [J]. J Clin Med, 2019, 8(5): 731.
|
| 25 |
Ropper AH. Neurosyphilis [J]. N Engl J Med, 2019, 381(14): 1358-1363.
|
| 26 |
Satyaputra F, Hendry S, Braddick M, et al. The laboratory diagnosis of syphilis [J]. J Clin Microbiol, 2021, 59(10): e0010021.
|
| 27 |
Gudowska-Sawczuk M, Mroczko B. Chemokine ligand 13 (CXCL13) in neuroborreliosis and neurosyphilis as selected spirochetal neurological diseases: a review of its diagnostic significance [J]. Int J Mol Sci, 2020, 21(8): 2927.
|
| 28 |
Maric LS, Lepej SZ, Gorenec L, et al. Chemokines CXCL10, CXCL11, and CXCL13 in acute disseminated encephalomyelitis, non-polio enterovirus aseptic meningitis, and neuroborreliosis: CXCL10 as initial discriminator in diagnostic algorithm? [J]. Neurol Sci, 2018, 39(3): 471-479.
|
| 29 |
Tuddenham S, Ghanem KG. Neurosyphilis: knowledge gaps and controversies [J]. Sex Transm Dis, 2018, 45(3): 147-151.
|
| 30 |
Kazanietz MG, Durando M, Cooke M. CXCL13 and its receptor CXCR5 in cancer: inflammation, immune response, and beyond [J]. Front Endocrinol (Lausanne), 2019, 10: 471.
|
| 31 |
Marra CM. Alternatives to the cerebrospinal fluid venereal disease research laboratory test for neurosyphilis diagnosis [J]. Sex Transm Dis, 2021, 48(8S): S54-S57.
|
| 32 |
Yu Q, Cheng Y, Wang Y, et al. Aberrant humoral immune responses in neurosyphilis: CXCL13/CXCR5 play a pivotal role for B-cell recruitment to the cerebrospinal fluid [J]. J Infect Dis, 2017, 216(5): 534-544.
|
| 33 |
Pilz G, Steger R, Wipfler P, et al. Beyond LNB: real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases [J]. J Neuroimmunol, 2020, 338: 577087.
|